Welcome to our dedicated page for Nasus Pharma Ltd. news (Ticker: NSRX), a resource for investors and traders seeking the latest updates and insights on Nasus Pharma Ltd. stock.
Nasus Pharma Ltd. (NSRX) is a clinical-stage pharmaceutical company whose news flow centers on the development of intranasal powder products for acute and emergency medical conditions. As a NYSE American–listed issuer and foreign private filer, the company regularly releases updates that are of interest to investors following emerging healthcare and drug delivery platforms.
News about Nasus Pharma frequently highlights progress in its lead program, NS002, an investigational intranasal epinephrine powder formulation being developed as a needle-free alternative to epinephrine autoinjectors for anaphylaxis. Coverage includes early clinical trial results, regulatory milestones such as Health Canada authorization for a Phase 2 study, and announcements related to dosing of participants and study design details.
Company press releases also address corporate and capital markets events. These include the pricing and closing of its initial public offering, the approval and commencement of trading of its ordinary shares on the NYSE American under the symbol NSRX, and ceremonial milestones such as ringing the closing bell at the New York Stock Exchange. Such items provide context on Nasus Pharma’s transition to the public markets and its stated use of proceeds to advance the intranasal epinephrine program and general corporate activities.
In addition, Nasus Pharma issues news on strategic collaborations and leadership changes. Announcements have described expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support development and planned commercialization of NS002 through device technology, development services, and supply arrangements. Leadership updates, such as the appointment of an Executive Vice President and Chief Financial Officer, are also disclosed, along with shareholder communications like the CEO’s letter outlining clinical, regulatory, and corporate priorities.
Investors and observers who follow NSRX news can use this page to review company press releases and related coverage that track Nasus Pharma’s clinical development, regulatory interactions, collaborations, governance developments, and capital markets activities over time.
Nasus Pharma (NYSE: NSRX) announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer effective Nov 20, 2025. Rubin brings more than two decades of financial leadership in biotechnology and pharma and will lead corporate finance, financial planning, capital strategy, and investor relations as Nasus advances its intranasal therapeutic pipeline toward clinical and commercial milestones.
Rubin previously served as CFO at Protalix BioTherapeutics and BrainStorm Cell Therapeutics and held treasury leadership at Teva. He holds a BA in Business Management and an MBA in Accounting and Finance, both summa cum laude. Company leaders said Rubin’s capital markets experience will support Nasus’s growth phase.
Nasus Pharma (NYSE: NSRX) received a No-Objection Letter from Health Canada on Nov 6, 2025, clearing the company to proceed with a planned Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder for anaphylaxis.
The authorization confirms acceptability of the proposed trial design, provided safety data, and manufacturing information, and enables Nasus to advance toward initiating the Phase 2 study using its proprietary Nasax technology.
Nasus Pharma (NYSE: NSRX) announced on October 8, 2025 expanded agreements with Aptar France and AptarGroup to support development and planned commercialization of NS002, an intranasal powder epinephrine candidate.
The collaboration secures a commercially proven Unit Dose System technology, access to Aptar's manufacturing, supply‑chain and technical expertise, and establishes a framework to support regulatory submissions to the FDA and EMA, aiming to accelerate NS002's path to market and reduce development risk.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The virtual presentation will be delivered by CEO Dan Teleman on September 5, 2025, from 7:00-7:30 AM ET.
The company will also be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company, celebrated its NYSE American listing with a Closing Bell ceremony on August 25, 2025. The company specializes in developing innovative intranasal products for emergency medical conditions.
Led by CEO Dan Teleman, Nasus Pharma is advancing its proprietary intranasal powder technology platform, focusing on treatments for severe allergic reactions and anaphylaxis. The company aims to provide needle-free, fast-acting alternatives to traditional emergency medications, particularly targeting families affected by anaphylaxis who currently rely on carrying Epinephrine.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has successfully completed its Initial Public Offering (IPO). The company raised $10 million in gross proceeds through the offering of 1,250,000 ordinary shares at $8.00 per share.
Trading commenced on the NYSE American exchange on August 13, 2025, under ticker NSRX. The underwriters have a 45-day option to purchase up to 187,500 additional shares. Proceeds will fund the development of their intranasal Epinephrine program, including manufacturing scale-up and Phase 2 studies, along with general corporate purposes.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced the pricing of its Initial Public Offering (IPO). The company is offering 1,250,000 ordinary shares at $8.00 per share, aiming to raise $10 million in gross proceeds.
The company has granted underwriters a 45-day option to purchase up to 187,500 additional shares. Trading will commence on NYSE American LLC on August 13, 2025, under the symbol "NSRX". The proceeds will primarily fund the development of their intranasal Epinephrine program, including manufacturing scale-up and Phase 2 studies.